Skip to Content
Morningstar

Swedish Orphan Biovitrum AB SOBI

Morningstar Rating
Unlock
Stock XSTO Rating as of
SEK 293.80 −5.20 (1.74%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Price vs Fair Value

View History
SOBI is trading at a 677% premium.
Price
SEK 293.80
Fair Value
SEK 999.00
Uncertainty
High
1-Star Price
SEK 375.64
5-Star Price
SEK 533.40
Economic Moat
Nbsdpd
Capital Allocation
Ngjlqcph

Bulls Say, Bears Say

Bulls

Sobi’s Elocta was first-to-market in Europe among EHL treatments in hemophilia A, and Sobi's potential launch of once-weekly Altuviiio in 2024 in Europe should extend the firm's franchise despite competition.

Bears

With a growing number of hemophilia A and B competitors, Sobi could have a difficult time recruiting new patients and maintaining pricing.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SOBI is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
SEK 299.00
Day Range
SEK 292.00–299.20
52-Week Range
SEK 189.03–300.00
Bid/Ask
SEK 294.80 / SEK 295.20
Market Cap
SEK 100.63 Bil
Volume/Avg
414,494 / 348,109

Key Statistics

Price/Earnings (Normalized)
43.16
Price/Sales
4.23
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Growth
Total Number of Employees
1,772
Website
https://www.sobi.com

Competitors

Valuation

View More
Metric
SOBI
ALNY
4502
Price/Earnings (Normalized)
 43.16—16.11
Price/Book Value
 2.77—0.92
Price/Sales
 4.2314.701.57
Price/Cash Flow
 16.94137.947.69
Price/Earnings
SOBI
ALNY
4502

Financial Strength

Metric
SOBI
ALNY
4502
Quick Ratio
 0.492.860.51
Current Ratio
 0.733.171.11
Interest Coverage
 2.81−2.381.35
Quick Ratio
SOBI
ALNY
4502

Profitability

Metric
SOBI
ALNY
4502
Return on Assets (Normalized)
 3.24%−2.47%5.19%
Return on Equity (Normalized)
 7.16%—11.01%
Return on Invested Capital (Normalized)
 6.55%−7.00%7.28%
Return on Assets
SOBI
ALNY
4502
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
GwzlmggmgWvxq$82.1 Bil
 Merck KGaA ADR
MKKGY
DnbxhrbswMxxdmlb$75.2 Bil
 Haleon PLC ADR
HLN
PmpfvnpsRtszd$41.4 Bil
 Viatris Inc
VTRS
SfbjsffkTqhl$14.4 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
QmcvpqvHlnhr$13.7 Bil
 Catalent Inc
CTLT
VrbslnvzQmylnf$10.6 Bil
 Perrigo Co PLC
PRGO
JxftjxzkWqnk$3.8 Bil
 Prestige Consumer Healthcare Inc
PBH
PvczyvdRxwzq$3.5 Bil
 Curaleaf Holdings Inc
CURLF
LqmyngkjDzbs$3.0 Bil
 Green Thumb Industries Inc
GTBIF
MfvkspvvRqv$2.7 Bil

Sponsor Center